Du är här

2016-02-16

Enzymatica AB: Strong growth in 2015 and acquisition for international expansion

FY 2015

* Net sales increased to SEK 27.9 (19.1) million.
* Loss after tax came in at SEK -40.8 (-32.4) million.
* Earnings per share totaled SEK -1.64 (-1.41).

Q4

* Net sales increased to SEK 11.1 (8.7) million.
* Loss after tax came in at SEK -11.2 (-12.3) million.
* Earnings per share totaled SEK -0.45 (-0.49).
* Cash and cash equivalents were SEK 8.1 (37.9) million.

Significant events after the end of the period

Enzymatica signed an agreement to acquire Icelandic company Zymetech via a
non-cash issue in January 2016. The transaction is to be approved at an
extraordinary general meeting on February 15. The capital contributed by the
subsequent cash issues will
enable a stronger focus on commercial investments and international
geographic expansion. For more information, please seewww.enzymtica.se

Enzymatica received a bridge loan from ALMI on February 5 in the amount of SEK
5 million in conjunction with the agreement to acquire Zymetech.

---------------------------------------------------------------------------------
| Financial ratios |
| (SEK million) Oct-Dec Oct-Dec Full year Full year |
| |
| 2015 2014 2015 2014 |
| Net sales 11.1 8.7 27.9 19.1 |
| Gross margin, % 65 79 70 74 |
| Operating profit/loss -11.0 -12.2 -40.4 -32.7 |
| Cash flow from operating activities -12.2 -13.0 -37.7 -40.7 |
| Average number of employees 17 14 16 13 |
---------------------------------------------------------------------------------
CEO statement: Foundations laid for international expansion with Zymetech
acquisition

In 2015, we increased our sales by 46 percent to SEK 27.9 million, in
comparison to around SEK 19 million the year prior, as a result of continuing
strong sales on the Swedish market, where ColdZyme® has reached a market
share of approximately 5 percent. Calculated in SEK, our product has thus
established itself among the best-selling cold products in Swedish
pharmacies. Consumers have responded very positively to our smaller package,
OneCold, especially in Sweden.
The increased sales and lower overhead costs contributed to an improvement in
our operating loss for Q4 compared to the same period in 2014.
In the UK, Enzymatica strengthened its presence by signing an agreement with
pharmacy chain Lloyds in October to begin sales in December. The agreement
will make ColdZyme available in an additional 1,300 pharmacies.
We took several key steps in our international expansion in Q4. We signed an
agreement with distributor Tamro in Finland, which kicked off ColdZyme sales
in November. A short time later, Enzymatica also signed a distribution
agreement with Spanish pharmaceutical company Esteve for Spain and Andorra to
launch the product in January 2016. Under both of these agreements, our
distributor pays for the marketing costs for the respective market.
In 2015, we put in a lot of work on building a foundation for our continuing
internationalization. Our work on establishing a quality management system
and other measures for compliance with international directives for medical
devices has been necessary and important to meet the high quality
requirements of partners. We also planned for the upcoming clinical follow-up
study of ColdZyme in the UK in 2016 and continued our market entry activities
in the Nordic region and other selected markets.
The next step to facilitate international expansion is the bid for our
Icelandic partner Zymetech, which I see as a key strategic complement to
Enzymatica's business. The acquisition gives us sole ownership of the patent
protection for ColdZyme throughout Europe and a dozen or so additional
countries. This gives us the ability to offer distributors exclusive
distribution rights, which facilities our international expansion.
We also get control over enzyme production as well as access to international
research expertise and Zymetech's research portfolio. The proposed new share
issues create the financial stability to enable us to be more commercially
aggressive and thus foster a substantial long-term future increase in sales.
Fredrik Lindberg, CEO

For questions about this report, please contact:

Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email:fredrik.lindberg@enzymatica.com

Johan Wennerholm, CFO, Enzymatica AB
Tel: +46 (0)730-42 99 97 | Email:johan.wennerholm@enzymatica.com

Enzymatica at a glance

Enzymatica AB is a life science company whose business concept is to provide
effective relief for some of the most common diseases where viruses and
bacteria play a decisive role. In a short period of time, the company
developed ColdZyme®, a unique mouth spray for fighting colds, launched the
product in six markets and reached a position over the past winter as one of
the most-sold cold products in Swedish pharmacies measured in SEK. Enzymatica
has its own sales organization in Scandinavia and collaborates with a
contract sales organization in the UK.

Our development focuses on medical devices for upper respiratory tract
infections and oral health. An enzyme from deep-sea fish is a key
sub-component in product development.

Enzymatica was founded in 2007, has its head office in Lund, Sweden and has
been listed on the Nasdaq First North since June 15, 2015.

Enzymatica Year-End Report 2015
http://hugin.info/160850/R/1986412/728802.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire

HUG#1986412

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.